Overview

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

Status:
Completed

Trial end date:
2004-11-01

Target enrollment:

Participant gender:

Summary

This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anti-Inflammatory Agents, Non-Steroidal
Dexlansoprazole
Esomeprazole
Lansoprazole
Pantoprazole